Claims for Patent: 11,110,074
✉ Email this page to a colleague
Summary for Patent: 11,110,074
| Title: | Methods of improving the pharmacokinetics of doxepin |
| Abstract: | Methods of improving the pharmacokinetics of doxepin in a patient. |
| Inventor(s): | Casseday; Cara Baron (San Diego, CA), Ludington; Elizabeth (San Diego, CA), Skinner; Michael (San Diego, CA), Dube; Susan E. (Carlsbad, CA), Rogowski; Roberta L. (Rancho Santa Fe, CA), Jochelson; Philip (San Diego, CA), Mansbach; Robert (San Diego, CA) |
| Assignee: | Currax Pharmaceuticals LLC (Brentwood, TN) |
| Application Number: | 16/876,492 |
| Patent Claims: |
1. A method of treating insomnia, the method comprising: administering between about 0.5 mg and 7 mg doxepin to a patient in need thereof, wherein the doxepin is administered at least
3 hours after consuming a meal to provide faster onset of action.
2. The method of claim 1, wherein the doxepin is administered in an amount of about 3 milligrams. 3. The method of claim 1 wherein the doxepin is administered in an amount of about 6 milligrams. 4. The method of claim 1 wherein the doxepin is administered as a tablet, capsule or liquid. 5. The method of claim 1, wherein the doxepin is administered as a unit dosage form. 6. The method of claim 1, wherein the doxepin is administered as an oral dosage form. 7. The method of claim 1, wherein the doxepin helps the patient fall asleep. 8. The method of claim 1, wherein the doxepin helps the patient stay asleep. 9. The method of claim 1, wherein administration of doxepin to a group of patients after a high fat meal provides an increase in area under the curve (AUK) compared to administration of doxepin to a group of fasted patients. 10. The method of claim 9, wherein the increase in AUC is about 41%. 11. The method of claim 1, wherein administration of doxepin to a group of patients after a high fat meal provides an increase in maximum plasma concentration (C.sub.max) compared to administration of doxepin to a group of fasted patients. 12. Claim 11, wherein the increase in C.sub.max is about 15%. 13. The method of claim 1, wherein the doxepin is administered within about one hour of bedtime. 14. The method of claim 1, wherein the doxepin is administered as doxepin hydrochloride. 15. A method of treating insomnia in a patient in need thereof, the method comprising: administering between about 0.5 mg and about 7 mg doxepin to the patient at least 3 hours after consuming a meal to provide faster onset of action, wherein administration of doxepin to a group of patients after a meal compared to administration of doxepin to a group of fasted patients provides: an increase in area under the curve (AUC) of doxepin; an increase in maximum plasma concentration (Cmax) of doxepin; or a delay in median time to reach maximum plasma concentration (T.sub.max) of doxepin. 16. The method of claim 15, wherein the increase in AUC is about 41%. 17. The method of claim 15, wherein the increase in maximum plasma concentration (C.sub.max) is about 15%. 18. The method of claim 15, wherein the a delay in median time to reach maximum plasma concentration (T.sub.max) is about 3 hours. 19. The method of claim 15, wherein administration of doxepin to a group of fasted patients provides: an increase in area under the curve (AUC) is about 41%; an increase in maximum plasma concentration (C.sub.max) is about 15%; or a delay in median time to reach maximum plasma concentration (T.sub.max) is about 3 hours. |
